Education
About Us
Working with TipRanks
Follow Us
Stevanato Group (STVN)
NYSE:STVN
STVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.56 - $33.49
Previous CloseN/A
Volume58.94K
Average Volume (3M)377.49K
Market Cap
$7.29B
Enterprise Value$5.77B
Total Cash (Recent Filing)€98.27M
Total Debt (Recent Filing)€428.97M
Price to Earnings (P/E)45.9
Beta0.59
Next Earnings
May 07, 2025EPS Estimate
0.1Last Dividend Ex-Date
Jun 04, 2024Dividend Yield0.27%
Share Statistics
EPS (TTM)0.47
Shares Outstanding49,604,650
10 Day Avg. Volume427,639
30 Day Avg. Volume377,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.70Price Target Upside13.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Stevanato Group News
PremiumCompany Announcements
Stevanato Group’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Stevanato Group Achieves Record Revenue, Eyes Growth
PremiumCompany Announcements
Stevanato Group Seeks New Board Member Following Unexpected Vacancy
---
Bulls Say, Bears Say
Bulls Say
Capacity ExpansionThe accelerated capacity expansion gives STVN a unique opportunity to capture share in the sterile cartridge market.
Market PositionSTVN has market leading positions in the attractive biopharmaceutical injectables end market, with a strong/broad product portfolio.
Bears Say
Cash FlowIn FY25, free cash flow is expected to be negative, but capex is expected to normalize in FY26 and turn free cash flow positive.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
STVN FAQ
What was Stevanato Group’s price range in the past 12 months?
Stevanato Group lowest stock price was $16.56 and its highest was $33.49 in the past 12 months.
What is Stevanato Group’s market cap?
Stevanato Group’s market cap is $7.29B.
When is Stevanato Group’s upcoming earnings report date?
Stevanato Group’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Stevanato Group’s earnings last quarter?
Stevanato Group released its earnings results on Mar 06, 2025. The company reported $0.206 earnings per share for the quarter, beating the consensus estimate of $0.2 by $0.007.
Is Stevanato Group overvalued?
According to Wall Street analysts Stevanato Group’s price is currently Undervalued.
Does Stevanato Group pay dividends?
Stevanato Group pays a Annually dividend of $0.057 which represents an annual dividend yield of 0.27%. See more information on Stevanato Group dividends here
What is Stevanato Group’s EPS estimate?
Stevanato Group’s EPS estimate is 0.1.
How many shares outstanding does Stevanato Group have?
Stevanato Group has 49,604,650 shares outstanding.
What happened to Stevanato Group’s price movement after its last earnings report?
Stevanato Group reported an EPS of $0.206 in its last earnings report, beating expectations of $0.2. Following the earnings report the stock price went up 8.604%.
Which hedge fund is a major shareholder of Stevanato Group?
Currently, no hedge funds are holding shares in STVN
---
Stevanato Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.70 (13.72% Upside)
$25.70 (13.72% Upside)
Blogger Sentiment
Bullish
STVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.77%
12-Months-Change
Fundamentals
Return on Equity
9.40%
Trailing 12-Months
Asset Growth
5.38%
Trailing 12-Months
Company Description
Stevanato Group
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.
---
STVN Company Deck
---
STVN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted growth in high-value solutions and the Biopharmaceutical and Diagnostic Solutions segment, along with significant improvements in free cash flow and progress in expansion projects. However, challenges remain in the Engineering segment and vial revenue, with a notable decline in gross profit margins. The company's efforts to address these challenges and invest in growth areas indicate a balanced outlook.Read More>---
STVN Stock 12 Month Forecast
Average Price Target
$25.70
▲(13.72% Upside)
Technical Analysis
Best Analysts Covering STVN
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+19.23%
reiterated a buy rating 7 days ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +19.23% per trade.
---